324 related articles for article (PubMed ID: 29654440)
1. Management of cystic prolactinomas: a review.
Nakhleh A; Shehadeh N; Hochberg I; Zloczower M; Zolotov S; Taher R; Daoud Naccache D
Pituitary; 2018 Aug; 21(4):425-430. PubMed ID: 29654440
[TBL] [Abstract][Full Text] [Related]
2. The Role of Surgery in the Management of Prolactinomas.
Donoho DA; Laws ER
Neurosurg Clin N Am; 2019 Oct; 30(4):509-514. PubMed ID: 31471058
[TBL] [Abstract][Full Text] [Related]
3. Significance of surgical management for cystic prolactinoma.
Ogiwara T; Horiuchi T; Nagm A; Goto T; Hongo K
Pituitary; 2017 Apr; 20(2):225-230. PubMed ID: 27757801
[TBL] [Abstract][Full Text] [Related]
4. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
5. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
7. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
8. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
9. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Prolactinoma.
Inder WJ; Jang C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
[TBL] [Abstract][Full Text] [Related]
11. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
12. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
13. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
15. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
17. Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy.
Witek P; Zieliński G; Maksymowicz M; Zgliczyński W
Neuro Endocrinol Lett; 2012; 33(5):483-8. PubMed ID: 23090264
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
19. Current Status of Surgery in Management of Prolactinomas.
Panigrahi MK; Chandrasekhar YBVK; Vooturi S
Neurol India; 2020; 68(Supplement):S39-S43. PubMed ID: 32611891
[TBL] [Abstract][Full Text] [Related]
20. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
